Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Management of Cardiovascular Risk Factors and Medical Therapy

  • N. Diehm
  • J. Schmidli
  • C. Setacci
  • J. -B. Ricco
  • G. de Donato
  • F. Becker
  • H. Robert-Ebadi
  • P. Cao
  • H. H. Eckstein
  • P. De Rango
  • M. Teraa
  • F. L. Moll
  • F. Dick
  • A. H. Davies
  • M. Lepantalo
  • Jan Apelqvist
Publishing year: 2011
Language: English
Pages: 33-42
Publication/Series: European Journal of Vascular and Endovascular Surgery
Volume: 42
Issue: Suppl. 2
Document type: Journal article
Publisher: Elsevier

Abstract english

Critical limb ischaemia (CLI) is a particularly severe manifestation of lower limb atherosclerosis posing a major threat to both limb and life of affected patients. Besides arterial revascularisation, risk-factor modification and administration of antiplatelet therapy is a major goal in the treatment of CLI patients. Key elements of cardiovascular risk management are smoking cessation and treatment of hyperlipidaemia with dietary modification or statins. Moreover, arterial hypertension and diabetes mellitus should be adequately treated. In CLI patients not suitable for arterial revascularisation or subsequent to unsuccessful revascularisation, parenteral prostanoids may be considered. CLI patients undergoing surgical revascularisation should be treated with beta blockers. At present, neither gene nor stem-cell therapy can be recommended outside clinical trials. Of note, walking exercise is contraindicated in CLI patients due to the risk of worsening pre-existing or causing new ischaemic wounds. CLI patients are oftentimes medically frail and exhibit significant comorbidities. Co-existing coronary heart and carotid as well as renal artery disease should be managed according to current guidelines. Considering the above-mentioned treatment goals, interdisciplinary treatment approaches for CLI patients are warranted. Aim of the present manuscript is to discuss currently existing evidence for both the management of cardiovascular risk factors and treatment of co-existing disease and to deduct specific treatment recommendations. (C) 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.


  • Surgery
  • Conservative treatment
  • Medication
  • Risk factor modification


  • Genomics, Diabetes and Endocrinology
  • ISSN: 1532-2165
E-mail: jan [dot] apelqvist [at] med [dot] lu [dot] se


Genomics, Diabetes and Endocrinology

+46 40 33 23 84

+46 74 025 81 66


Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00